KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Share-based Compensation (2016 - 2025)

Opko Health (OPK) has disclosed Share-based Compensation for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 3.33% year-over-year to $2.9 million, compared with a TTM value of $10.7 million through Dec 2025, down 2.73%, and an annual FY2025 reading of $10.7 million, down 2.73% over the prior year.
  • Share-based Compensation was $2.9 million for Q4 2025 at Opko Health, down from $3.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.6 million in Q1 2022 and bottomed at $2.2 million in Q2 2025.
  • Average Share-based Compensation over 5 years is $3.3 million, with a median of $2.9 million recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 187.76% in 2022, then plummeted 64.55% in 2023.
  • Year by year, Share-based Compensation stood at $3.7 million in 2021, then fell by 13.58% to $3.2 million in 2022, then fell by 15.62% to $2.7 million in 2023, then increased by 11.11% to $3.0 million in 2024, then decreased by 3.33% to $2.9 million in 2025.
  • Business Quant data shows Share-based Compensation for OPK at $2.9 million in Q4 2025, $3.0 million in Q3 2025, and $2.2 million in Q2 2025.